SCHEMBL883352

SCHEMBL883352

CC(C)(C)CC(=O)Nc1c(NC2CCC2)nc2c(C(F)(F)F)cccn2c1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 3/20 0.37
KCNQ2 O43526 3/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
GAA P10253 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
CYP2C19 P33261 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAPK3 P27361 3/20 0.34
FGFR3 P22607 1/20 0.34
MAT2A P31153 1/20 0.34
KMT2A Q03164 1/20 0.34
ULK1 O75385 1/20 0.34
RXFP1 Q9HBX9 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
F7 P08709 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL876306 0.85 SMN1; SMN2 (0.40) KCNQ3KCNQ2TP53MAPTCYP1A2
SCHEMBL883428 0.83 SMN1; SMN2 (0.40) KCNQ3KCNQ2TP53MAPTCYP1A2
SCHEMBL875449 0.81 SMN1; SMN2 (0.42) KCNQ3KCNQ2TP53MAPTCYP1A2
SCHEMBL875508 0.79 PRSS1 (0.35) TP53MAPTFGFR3MAT2AKMT2A
SCHEMBL883703 0.72 LMNA (0.44) TP53MAPTGAAHPGDSMN1; SMN2
SCHEMBL15106487 0.72 TP53 (0.38) KCNQ3KCNQ2TP53MAPTHPGD
SCHEMBL15106118 0.72 KCNQ2 (0.36) KCNQ3KCNQ2MAPTSMN1; SMN2KMT2A
SCHEMBL883609 0.70 KCNQ2 (0.35) KCNQ3KCNQ2
SCHEMBL10074404 0.68 KDM4E (0.49) TP53MAPTGAAHPGDSMN1; SMN2
SCHEMBL875494 0.67 KDM4E (0.50) KCNQ2TP53MAPTGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130184294-A1 Pyrimidones for Treatment of Potassium Channel Related Diseases PFIZER INC. (US) 2013-07-18 US disclosed
US-20130184294-A1 Pyrimidones for Treatment of Potassium Channel Related Diseases PFIZER INC. (US) 2013-07-18 US disclosed
WO-2012038850-A1 PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES PFIZER INC. (US) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184294-A1 Pyrimidones for Treatment of Potassium Channel Related Diseases KCNQ5, KCNQ1, KCNQ3 KCNQ3 3/4885KCNQ2 4/4885TP53 3685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.